^
Association details:
| Biomarker: | VTCN1 overexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | felmetatug vedotin (PF-08046048) (Microtubule inhibitor, B7-H4-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SGN-B7H4V induces immunomodulatory changes to the tumor microenvironment and pairs well with an anti-PD1 agent in a preclinical model
Published date:
11/08/2022
Excerpt:
Treatment of B7-H4-expressing syngeneic tumors with SGN-B7H4V led to immunomodulatory changes in the TME, including recruitment of multiple immune cell types and upregulation of immune-related genes that have been previously associated with response to anti-PD(L)1 agents. Moreover, SGN-B7H4V drove robust antitumor activity as well as durable immune memory as a monotherapy and in combination with an anti-PD1 agent... In preclinical models, SGN-B7H4V demonstrates robust antitumor activity accompanied by immunomodulatory changes in the TME. Moreover, SGN-B7H4V in combination with an anti-PD1 agent led to improved antitumor activity and elicited durable immune memory.
Secondary therapy:
PD1 inhibitor
DOI:
10.1136/jitc-2022-SITC2022.1190
Source:
Title:
SGN-B7H4V induces immunomodulatory changes to the tumor microenvironment and pairs well with an anti-PD1 agent in a preclinical model
Published date:
11/08/2022
Excerpt:
Treatment of B7-H4-expressing syngeneic tumors with SGN-B7H4V led to immunomodulatory changes in the TME, including recruitment of multiple immune cell types and upregulation of immune-related genes that have been previously associated with response to anti-PD(L)1 agents. Moreover, SGN-B7H4V drove robust antitumor activity as well as durable immune memory as a monotherapy and in combination with an anti-PD1 agent...In preclinical models, SGN-B7H4V demonstrates robust antitumor activity accompanied by immunomodulatory changes in the TME. Moreover, SGN-B7H4V in combination with an anti-PD1 agent led to improved antitumor activity and elicited durable immune memory.
DOI:
10.1136/jitc-2022-SITC2022.1190
